GI 6207

Drug Profile

GI 6207

Alternative Names: GI-6207; Recombinant Saccharomyces cerevisiae-CEA (610D)

Latest Information Update: 30 Aug 2017

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator GlobeImmune
  • Class Cancer vaccines; Yeasts
  • Mechanism of Action Carcinoembryonic antigen inhibitors; T lymphocyte stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Phase II Thyroid cancer
  • Phase I Solid tumours

Most Recent Events

  • 28 Aug 2017 NantCell acquires GI 6207 from GlobeImmune
  • 20 Jun 2017 NantCell plans the phase Ib/II QUILT-3.048 trial for Urogenital cancer (Second-line therapy or greater, Combination therapy) (NCT03197571)
  • 02 Jun 2017 NantCell plans the phase Ib/II QUILT-3.044 trial for Non-small cell lung cancer (Combination therapy, Second-line therapy or greater) (NCT03169738)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top